Mineralys Therapeutics, Inc. MLYS Interest coverage
Interest coverage at other companies
Other financials
Where this comes from
Calculated from Mineralys Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s interest coverage.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s interest coverage?
- Mineralys Therapeutics, Inc. (MLYS) reported interest coverage of -8.7× in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s interest coverage changed year-over-year?
- Mineralys Therapeutics, Inc.'s interest coverage increased by 44.0% year-over-year, from -15.5× to -8.7×.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s interest coverage?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s interest coverage has grown at a -17.1% compound annual growth rate (CAGR), from -18.8× to -10.7×.
- What does interest coverage mean?
- Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.